Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
January 25, 2017
(GLOBE NEWSWIRE via COMTEX) –ObsEva SA / ObsEva SA Announces Pricing of Initial Public Offering . Processed and transmitted by…
Read morepress release
January 17, 2017
Geneva, Switzerland, 17 January 2017 – ObsEva SA (ObsEva), a biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Read morepress release
January 13, 2017
– First-in-class orally active prostaglandin F2α receptor antagonist designed to safely control inflammation, uterine contractions, membrane ruptures and cervical changes that…
Read moreMay 28, 2021
June 9, 2020
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840